Apelin-13 attenuates motor impairments and prevents the changes in synaptic plasticity-related molecules in the striatum of Parkinsonism rats

Peptides. 2019 Jul:117:170091. doi: 10.1016/j.peptides.2019.05.003. Epub 2019 May 21.

Abstract

The striatum plays a critical role in motor control and also learning and memory of motor skills. It has been reported that striatal synaptic components are significantly decreased in dopaminergic-denervated striatum. In this study the effects of apelin-13 were investigated on motor disorders and striatal synaptosomal expression of PSD-95, neurexin1, neuroligin, metabotropic glutamate receptor (mGlu R1) and dopaminergic receptors (DR1 and DR2) in rat parkinsonism experimental model. 6-hydroxydopamine (6-OHDA) was injected into the substantia nigra. Apelin-13 (1, 2 and 3 μg/rat) was administered into the substantia nigra one week after the 6-OHDA injection. Accelerating rotarod, beam-balance, beam-walking and bar tests were performed one month after the apelin injection. Immunohistochemistry staining of dopaminergic neurons was performed. The levels of synaptic proteins were determined by immunoblotting. 6-OHDA-treated animals showed a significant impairment in motor-skill tasks and a dramatically change in the expression levels of mentioned proteins. Apelin-13 (3 μg/rat) significantly attenuates the motor impairments and prevents the changes in striatal synaptic elements in 6-OHDA-treated animals. In addition, it could rescue the dopaminergic neurons of the substantia nigra. The data will potentially extend the possible benefic aspect of apelin in neurodegenerative disorders.

Keywords: 6-OHDA; Apelin-13; Motor impairment; Parkinson’s disease; Striatum; Synaptic plasticity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Corpus Striatum / metabolism*
  • Corpus Striatum / pathology
  • Intercellular Signaling Peptides and Proteins / pharmacology*
  • Male
  • Motor Disorders / chemically induced
  • Motor Disorders / drug therapy*
  • Motor Disorders / metabolism
  • Motor Disorders / pathology
  • Neuronal Plasticity / drug effects*
  • Oxidopamine / adverse effects
  • Oxidopamine / pharmacology
  • Parkinson Disease, Secondary / chemically induced
  • Parkinson Disease, Secondary / drug therapy*
  • Parkinson Disease, Secondary / metabolism
  • Parkinson Disease, Secondary / pathology
  • Rats
  • Rats, Wistar

Substances

  • Intercellular Signaling Peptides and Proteins
  • apelin-13 peptide
  • Oxidopamine